Analyst Price Targets — CDNA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 5:17 pm | — | BTIG | $45.00 | $38.59 | TheFly | CareDx price target raised to $45 from $28 at BTIG |
| July 16, 2026 2:08 pm | — | Craig-Hallum | $35.00 | $36.91 | TheFly | Craig-Hallum ups CareDx price target after 'quite favorable' Medicare LCD |
| April 29, 2026 11:26 am | — | BTIG | $28.00 | $21.91 | TheFly | CareDx price target raised to $28 from $26 at BTIG |
| February 25, 2026 9:01 pm | Sung Ji Nam | BTIG | $26.00 | $18.46 | StreetInsider | CareDx, Inc (CDNA) PT Raised to $26 at BTIG |
| January 6, 2026 12:43 pm | — | Craig-Hallum | $26.00 | $19.81 | TheFly | CareDx downgraded to Hold from Buy at Craig-Hallum |
| December 15, 2025 11:25 am | Brandon Couillard | Wells Fargo | $18.00 | $20.57 | TheFly | CareDx price target raised to $18 from $14 at Wells Fargo |
| March 3, 2025 11:13 am | — | H.C. Wainwright | $25.00 | $21.13 | TheFly | CareDx price target lowered to $25 from $26 at H.C. Wainwright |
| November 5, 2024 10:13 am | Sung Ji Nam | BTIG | $35.00 | $22.90 | StreetInsider | CareDx, Inc (CDNA) PT Lowered to $35 at BTIG |
| August 19, 2024 7:50 am | Mark Massaro | BTIG | $40.00 | $33.00 | TheFly | CareDx upgraded to Buy from Neutral at BTIG |
| August 16, 2024 3:05 pm | Bill Bonello | Craig-Hallum | $40.00 | $32.98 | TheFly | CareDx price target raised to $40 from $32 at Craig-Hallum |
Latest News for CDNA
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the…
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx's transplant surveillance offerings in kidney,…
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CDNA.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.